Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label outpatient extension study of Staccato alprazolam in patients aged 12 years or older with stereotyped prolonged epileptic seizures
CTR20220335Phase 3Active
- Sponsor
- UCB
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alprazolam in epilepsy, sponsored by UCB. Primary endpoints: Frequency of treatment-emergent adverse events, Frequency of treatment-emergent adverse events leading to study withdrawal and 1 more. Started Jan 2023; status: active.
02
Drugs
alprazolam
03
Conditions
epilepsy
Beyond the preview
Go deeper on CTR20220335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220335.